Nanotechnology Companies

Add company into catalog:

Login: 
Password: 


  Registration / Why register?

BELLUS Health

BELLUS Health

They are focused on developing drugs for rare diseases, starting with conditions that affect the kidneys.

This company aims on  developing drugs for rare diseases, starting with conditions that affect the kidneys.

developing drugs for rare diseases, starting with conditions that affect the kidneys.

Their lead program is KIACTA™, a novel drug candidate actually in a Phase 3 Confirmatory Study for the treatment of AA amyloidosis, a rare disease resulting in renal dysfunction that often leads to dialysis and death.

BELLUS Health’s pipeline also includes a research-stage project for the treatment of AL amyloidosis, a rare disease in which amyloid protein builds up and causes dysfunction in various parts of the body.

BELLUS Health is based in Laval, Quebec and its shares trade under the ticker BLU on the Toronto Stock Exchange.

BELLUS Health’s pipeline also covers a research-stage project for the treatment of AL amyloidosis, a rare disease in which amyloid protein builds up and causes dysfunction in various parts of the body.

BELLUS Health is based in Laval, Quebec and its shares trade under the ticker BLU on the Toronto Stock Exchange.

The lead program is KIACTA™, a novel drug candidate currently in a Phase 3 Confirmatory Study for the treatment of AA amyloidosis, a rare disease resulting in renal dysfunction that often leads to dialysis and death. BELLUS Health is partnered with global private equity firm Auven Therapeutics for the development of KIACTA™.

The lead program is KIACTA™, a novel drug candidate currently in a Phase 3 Confirmatory Study for the treatment of AA amyloidosis, a rare disease resulting in renal dysfunction that often leads to dialysis and death. BELLUS Health is partnered with global private equity firm Auven Therapeutics for the development of KIACTA™.

The lead program is KIACTA™, a novel drug candidate currently in a Phase 3 Confirmatory Study for the treatment of AA amyloidosis, a rare disease resulting in renal dysfunction that often leads to dialysis and death. BELLUS Health is partnered with global private equity firm Auven Therapeutics for the development of KIACTA™.


Business Type: Nanotextile » | Biotechnology » | Electrotechnics » |

BELLUS Health

275 Armand-Frappier Blvd.
H7V 4A7 Laval

Phone: (450) 680-4500
webinfo@bellushealth.com
http://www.bellushealth.com


Share with friends:  

Next companies in category

TOPlist